Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable
stock fell Tuesday after the company said it plans to cut about 1,000 jobs in an effort to cut operating expenses. The announcement came as Biogen reported better-than-expected second-quarter financials, as earnings fell more than 20% with its fully approved Alzheimer's drug, Leqembi, not yet…
#biogen #leqembi #cambridge #chrisviehbacher #tecfidera #vumerity #plegridy #tysabri #centersformedicare #medicaidservices